New Drug Approvals
Follow New Drug Approvals on WordPress.com

FLAGS AND HITS

Flag Counter
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO

Archives

Categories

Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Researchgate

Anthony Melvin Crasto Dr.

  Join me on Facebook FACEBOOK   ...................................................................Join me on twitter Follow amcrasto on Twitter     ..................................................................Join me on google plus Googleplus

MYSELF

DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 36Yrs Exp. in the feld of Organic Chemistry,Working for AFRICURE PHARMA as ADVISOR earlier with GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, NO ADVERTISEMENTS , ACADEMIC , NON COMMERCIAL SITE, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution, ........amcrasto@gmail.com..........+91 9323115463, Skype amcrasto64 View Anthony Melvin Crasto Ph.D's profile on LinkedIn Anthony Melvin Crasto Dr.

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Verified Services

View Full Profile →

Recent Posts

Sanofi and Regeneron’s dupilumab for asthma. The partners have unveiled Phase IIa data at the American Thoracic Society meeting in Philadelphia on dupilumab, an interleukin 4 receptor which modulates signalling of both the IL-4 and IL-13 proteins, which are linked to inflammation


Dupilumab is a monoclonal antibody designed for the treatment of atopic diseases.It binds to the alpha subunit of the interleukin-4 receptor. Through blockade of IL-4R alpha, dupilumab modulates signaling of both the IL-4 and IL-13 pathway, which have been implicated in the pathophysiology of allergic disease.

This drug was developed by Regeneron Pharmaceuticals.

On May 21/2013 mid-stage data was presented at the American Thoracic Society meeting and published in the NEJM demonstrating a 87% reduction in asthma exacerbations in patients with moderate-to-severe allergic asthma.

The long-standing alliance between Sanofi and Regeneron looks to have scored another clinical goal, this time with dupilumab for asthma.

The partners have unveiled Phase IIa data at the American Thoracic Society meeting in Philadelphia on dupilumab, an interleukin 4 receptor which modulates signalling of both the IL-4 and IL-13 proteins, which are linked to inflammation. The 104-patient study enrolled 104 patients with moderate-to-severe, persistent asthma that was not well controlled with inhaled glucocorticosteroids (ICS) and long-acting beta agonist (LABA) therapy, and who had elevated blood or sputum eosinophils

FDA Gives Pediatric Approval to Japanese Encephalitis Vaccine


 

Intercell Announces Pediatric Approval of its Japanese Encephalitis Vaccine in the U.S.

read at

http://www.pharmalive.com/fda-gives-pediatric-approval-to-japanese-encephalitis-vaccine

B4U22AHZFPTW

Capsaicin- CONTROL RIOTS and has ANTICANCER PROPERTIES


Capsaicin

 

Capsaicin
Capsaicin
Heat Above Peak (SR: 15,000,000-16,000,000)

Capsaicin (pron.: /kæpˈseɪ.ɨsɪn/; 8-methyl-N-vanillyl-6-nonenamide, ( (CH3)2CHCH=CH(CH2)4CONHCH2C6H3-4-(OH)-3-(OCH3) ) is the active component of chili peppers, which are plants belonging to the genus Capsicum. It is an irritant for mammals, including humans, and produces a sensation of burning in any tissue with which it comes into contact. Capsaicin and several related compounds are called capsaicinoids and are produced as secondary metabolites by chili peppers, probably as deterrents against certain mammals and fungi.[2] Pure capsaicin is a volatile, hydrophobic, colorless, odorless, crystalline to waxy compound.

The compound was first extracted (albeit in impure form) in 1816 by Christian Friedrich Bucholz (1770–1818). He called it “capsicin,” after the genus Capsicum from which it was extracted. John Clough Thresh (1850–1932), who had isolated capsaicin in almost pure form, gave it the name “capsaicin” in 1876. But it was Karl Micko who first isolated capsaicin in pure form in 1898. Capsaicin’s empirical formula (chemical composition) was first determined by E. K. Nelson in 1919; he also partially elucidated capsaicin’s chemical structure. Capsaicin was first synthesized in 1930 by E. Spath and S. F. Darling.In 1961, similar substances were isolated from chili peppers by the Japanese chemists S. Kosuge and Y. Inagaki, who named them capsaicinoids.

In 1873 German pharmacologist Rudolf Buchheim(1820–1879) and in 1878 the Hungarian doctor Endre Hőgyesstated that “capsicol” (partially purified capsaicin) caused the burning feeling when in contact with mucous membranes and increased secretion of gastric juice.

Capsaicin is the main capsaicinoid in chili peppers, followed by dihydrocapsaicin. These two compounds are also about twice as potent to the taste and nerves as the minor capsaicinoids nordihydrocapsaicin, homodihydrocapsaicin, and homocapsaicin. Dilute solutions of pure capsaicinoids produced different types of pungency; however, these differences were not noted using more concentrated solutions.

Capsaicin is believed to be synthesized in the interlocular septum of chili peppers by addition of a branched-chain fatty acid to vanillylamine; specifically, capsaicin is made from vanillylamine and 8-methyl-6-nonenoyl CoA. Biosynthesis depends on the gene AT3, which resides at the pun1 locus, and which encodes a putative acyltransferase.

Besides the six natural capsaicinoids, one synthetic member of the capsaicinoid family exists. Vanillylamide of n-nonanoic acid (VNA, also PAVA) is used as a reference substance for determining the relative pungency of capsaicinoids.

Capsaicinoid name Abbrev. Typical
relative
amount
Scoville
heat units
Chemical structure
Capsaicin C 69% 16,000,000 Chemical structure of capsaicin
Dihydrocapsaicin DHC 22% 15,000,000 Chemical structure of dihydrocapsaicin
Nordihydrocapsaicin NDHC 7% 9,100,000 Chemical structure of nordihydrocapsaicin
Homodihydrocapsaicin HDHC 1% 8,600,000 Chemical structure of homodihydrocapsaicin
Homocapsaicin HC 1% 8,600,000 Chemical structure of homocapsaicin
Nonivamide PAVA 9,200,000 Chemical structure of nonivamide

Capsaicin is present in large quantities in the placental tissue (which holds the seeds), the internal membranes and, to a lesser extent, the other fleshy parts of the fruits of plants in the genus Capsicum. The seeds themselves do not produce any capsaicin, although the highest concentration of capsaicin can be found in the white pith of the inner wall, where the seeds are attached.

The seeds of Capsicum plants are predominantly dispersed by birds. The TRPV1 channel to which capsaicin binds does not respond to capsaicin and related chemicals in birds (avian vs mammalian TRPV1 show functional diversity and selective sensitivity). Chili pepper seeds consumed by birds pass through the digestive tract and can germinate later, but mammals have molar teeth, which destroy seeds and prevent them from germinating. Thus, natural selection may have led to increasing capsaicin production because it makes the plant less likely to be eaten by animals that do not help it reproduce.In addition, there is evidence that capsaicin evolved as an anti-fungal agent. The fungal pathogen, Fusarium, is known to infect wild chilies which reduces seed viability. Capsaicin deters the fungus, and in doing so limits this form of predispersal seed mortality.

In 2006, it was discovered that the venom of a certain tarantula species activates the same pathway of pain as is activated by capsaicin, the first demonstrated case of such a shared pathway in both plant and animal anti-mammal defense.

Food

Because of the burning sensation caused by capsaicin when it comes in contact with mucous membranes, it is commonly used in food products to give them added spice or “heat” (piquancy). In high concentrations, capsaicin will also cause a burning effect on other sensitive areas of skin. The degree of heat found within a food is often measured on the Scoville scale. In some cases people enjoy the heat; there has long been a demand for capsaicin-spiced food and beverages. There are many cuisines and food products featuring capsaicin such as hot sauce, salsa, and beverages.

For information on treatment, see the section Treatment after exposure.

It is common for people to experience pleasurable and even euphoriant effects from ingesting capsaicin. Folklore among self-described “chiliheads” attributes this to pain-stimulated release of endorphins, a different mechanism from the local receptor overload that makes capsaicin effective as a topical analgesic. In support of this theory, there is some evidence that the effect can be blocked by naloxone and other compounds that compete for receptor sites with endorphins and opiates.

Capsaicin is currently used in topical ointments, as well as a high-dose dermal patch (trade name Qutenza), to relieve the pain of peripheral neuropathy such as post-herpetic neuralgia caused by shingles It may be used in concentrations of between 0.025% and 0.25%. It may be used as a cream for the temporary relief of minor aches and pains of muscles and joints associated with arthritis, simple backache, strains and sprains, often in compounds with other rubefacients.[The treatment typically involves the application of a topical anesthetic until the area is numb. Then the capsaicin is applied by a therapist wearing rubber gloves and a face mask. The capsaicin remains on the skin until the patient starts to feel the “heat”, at which point it is promptly removed. Capsaicin is also available in large bandages (plasters) that can be applied to the back.

Capsaicin creams are used to treat psoriasis as an effective way to reduce itching and inflammation

According to animal and human studies, the oral intake of capsaicin may increase the production of heat by the body for a short time. Due to the effect on the carbohydrates breakdown after a meal, cayenne may also be used to regulate blood sugar levels

Capsaicin selectively binds to a protein known as TRPV1 that resides on the membranes of pain and heat sensing neurons TRPV1 is a heat activated calcium channel, which opens between 37 and 45 °C (98.6 and 113 °F, respectively). When capsaicin binds to TRPV1, it causes the channel to open below 37 °C (normal human body temperature), which is why capsaicin is linked to the sensation of heat. Prolonged activation of these neurons by capsaicin depletes presynaptic substance P, one of the body’s neurotransmitters for pain and heat. Neurons that do not contain TRPV1 are unaffected.

The result appears to be that the chemical mimics a burning sensation, the nerves are overwhelmed by the influx, and are unable to report pain for an extended period of time. With chronic exposure to capsaicin, neurons are depleted of neurotransmitters, leading to reduction in sensation of pain and blockade of neurogenic inflammation. If capsaicin is removed, the neurons recover.

The American Association for Cancer Research reports studies suggesting capsaicin is able to kill prostate cancer and lung cancer cells by causing them to undergo apoptosis.The studies were performed on tumors formed by human prostate cancer cell cultures grown in mouse models, and showed tumors treated with capsaicin were about one-fifth the size of the untreated tumors. There have been several mouse studies conducted in Japan and China that showed natural capsaicin directly inhibits the growth of leukemic cells. Capsaicin may be able to trigger apoptosis in human lung cancer cells as well.

Capsaicin is also the key ingredient in the experimental drug Adlea, which is in Phase 2 trials as a long-acting analgesic to treat post-surgical and osteoarthritic pain for weeks to months after a single injection to the site of pain. Moreover, it reduces pain resulting from rheumatoid arthritis as well as joint or muscle pain from fibromyalgia or other causes.

Less-lethal force

Capsaicin is also the active ingredient in riot control and personal defense pepper spray chemical agents. When the spray comes in contact with skin, especially eyes or mucous membranes, it is very painful, and breathing small particles of it as it disperses can cause breathing difficulty, which serves to discourage assailants. Refer to the Scoville scale for a comparison of pepper spray to other sources of capsaicin.

In large quantities, capsaicin can cause death. Symptoms of overdose include difficulty breathing, blue skin, and convulsions.The large amount needed to kill an adult human and the low concentration of capsaicin in chillies make the risk of accidental poisoning by chilli consumption negligible.

Ranbaxy Laboratories gets tentative approval for HIV combination therapy


HIV

pic credit-www.pharmaceutical-technology.com

http://www.allfordrugs.com/2013/05/22/ranbaxy-laboratories-gets-tentative-approval-for-hiv-combination-therapy/

or

http://www.pharmaceutical-technology.com/news/newsranbaxy-laboratories-gets-tentative-approval-for-hiv-combination-therapy?WT.mc_id=DN_News

The US Food and Drug Administration has granted tentative approval for a fixed dose formulation of two generic drugs for use in combination with antiretrovirals.

Lamivudine and tenofovir disoproxil fumarate tablets, manufactured by India’s Ranbaxy Laboratories, will not be available for marketing in the US because of existing patent protections, but will be eligible for purchase elsewhere under the President’s Emergency Plan for Aids Relief programme.

lamuvudine

Lamivudine (2′,3′-dideoxy-3′-thiacytidine, commonly called 3TC) is a potent nucleoside analog reverse transcriptase inhibitor (nRTI).

It is marketed by GlaxoSmithKline with the brand names Zeffix, Heptovir, Epivir, and Epivir-HBV.

Lamivudine has been used for treatment of chronic hepatitis B at a lower dose than for treatment of HIV. It improves the seroconversion of e-antigen positive hepatitis B and also improves histology staging of the liver. Long term use of lamivudine unfortunately leads to emergence of a resistant hepatitis B virus (YMDD) mutant. Despite this, lamivudine is still used widely as it is well tolerated.

tenofovir disoproxil fumarate

Tenofovir disoproxil fumarate (TDF or PMPA), marketed by Gilead Sciences under the trade name Viread, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (NRTIs), which block reverse transcriptase, a crucial virus enzyme in human immunodeficiency virus 1 (HIV-1) and hepatitis B virus infections.

 

 

TOP 10 CARDIOVASCULAR DRUGS, BY FIERCE PHARMA


READ ALL

 

http://www.fiercepharma.com/special-reports/top-10-cardio-drugs-2012

Nigerian scientists have confirmed in clinical settings and in animal models that eating moderate quantities of bitter cola does not just enhance sexual activity but have clinically significant analgesic/anti-inflammatory effects in knee osteoarthritis patients


Bitter-cola16-5-13

READ ALL AT

http://www.ngrguardiannews.com/index.php?option=com_content&view=article&id=121791:bitter-kola-boosts-libido-beats-osteoarthritis-researchers-confirm&catid=44:natural-health&Itemid=599 CORRECT LINK

http://www.ngrguardiannews.com/index.php?option=com_content&amp%3Bview=article&amp%3Bid=121791%3Abitter-kola-boosts-libido-beats-osteoarthritis-researchers-confirm&amp%3Bcatid=44%3Anatural-health&amp%3BItemid=599&goback=%2Egde_3554645_member_242583455

Transverse Myelitis PDFs and free access published articles


Transverse Myelitis PDFs and free access published articles 

Transverse myelitis is a neurological disorder caused by inflammation across both sides of one level, or segment, of the spinal cord. The segment of the spinal cord at which the damage occurs determines which parts of the body are affected.

Transverse myelitis
http://eradiology.bidmc.harvard.edu/LearningLab/central/Kaufman.pdf

Recurrent Myelitis Associated With Hepatitis C Infection
www.bcm.edu/neurology/pdf/poster_other_RecurrentMyelitis.pdf

Neuro MRI Ordering Guide
MRI_Ordering_Guide2_1_.pdf

General Information Regarding MS
General_information_regarding_ms.pdf

NMO-IgG predicts the outcome of recurrent optic neuritis
NMO-IgG Rose-Innes_article1.pdf

Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis
Patrick Waters, PhD; Sven Jarius, MD; Edward Littleton, MBBS, DPhil; Maria Isabel Leite, MD etal
Aquaporin-4 Antibodies in Neuromyelitis.pdf

Transverse myelitis – Case study
Transverse myelitis.pdf

Diagnosis of Transverse Myelitis: An Evaluation of the factors leading to Spinal Dysfunction
Including a Review of one patients’ experience
Diagnosis of Transverse Myelitis.pdf

Imaging Sciences Interesting Cases
Jacinto Camarena III, MD
IS_Case12.pdf

50 Free scholarly articles on Transverse myelitis

  1. Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices.
  2. Urinary retention in immunocompetent patient: acute transverse myelitis.
  3. Acute transverse myelitis in Buenos Aires, Argentina. A retrospective cohort study of 8 years follow up.
  4. Rhabdomyolysis, acute kidney injury and transverse myelitis due to naive heroin exposure.
  5. Longitudinally extensive transverse myelitis: a catastrophic presentation of a flare-up of systemic lupus erythematosus.
  6. Primary HIV infection with acute transverse myelitis.
  7. H1N1 vaccine-related acute transverse myelitis.
  8. Acute transverse myelitis following vaccination against H1N1 influenza: a case report.
  9. Acute transverse myelitis and acute motor axonal neuropathy developed after vaccinations against seasonal and 2009 A/H1N1 influenza.
  10. Optical coherence tomography evaluation of retinal nerve fiber layer in longitudinally extensive transverse myelitis.
  11. Clinical analysis of 6 cases of systemic lupus erythematosus complicated by transverse myelitis.
  12. Mycobacteria infection in incomplete transverse myelitis is refractory to steroids: a pilot study.
  13. Acute transverse myelitis associated with dengue viral infection.
  14. Idiopathic acute transverse myelitis in children: an analysis and discussion of MRI findings.
  15. Longitudinally extensive transverse myelitis following vaccination with nasal attenuated novel influenza A(H1N1) vaccine.
  16. Transverse myelitis associated with chronic viral hepatitis C.
  17. High-level cervical spinal cord stimulation used to treat intractable pain arising from transverse myelitis caused by schistosomiasis.
  18. Acute transverse myelitis: treatment of pain.
  19. Transverse myelitis associated to HCV infection.
  20. Acute transverse myelitis: a clinical review and algorithm for diagnostic intervention.
  21. Priapism in infantile transverse myelitis.
  22. Transverse myelitis spectrum disorders.
  23. Transverse myelitis as a presenting feature of late onset systemic lupus erythematosus.
  24. Acute transverse myelitis and Guillain-Barre overlap syndrome following influenza infection.
  25. Diffusion tensor imaging in idiopathic acute transverse myelitis.
  26. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis.
  27. Transverse myelitis due to human herpesvirus 6.
  28. Subacute transverse myelitis with Lyme profile dissociation.
  29. Transverse myelitis associated with systemic lupus erythematosus.
  30. Idiopathic recurrent transverse myelitis with syringomyelia: a case report.
  31. Acute transverse myelitis at the conus medullaris level after rabies vaccination in a patient with Behçet’s disease.
  32. Transverse myelitis in a patient with severe lupus nephritis: a case report.
  33. Transverse myelitis in 2 patients with Bartonella henselae infection (cat scratch disease).
  34. Transverse myelitis caused by varicella zoster: case reports.
  35. Transverse myelitis in systemic lupus erythematosus.
  36. Acute transverse myelitis following typhoid vaccination.
  37. Transverse myelitis following spinal anesthesia.
  38. Neuromyelitis optica IgG status in acute partial transverse myelitis.
  39. Neurosyphilis manifesting as spinal transverse myelitis.
  40. Etanercept induced multiple sclerosis and transverse myelitis.
  41. Acute transverse myelitis following hepatitis E virus infection.
  42. Transverse myelitis due to trypanosomiasis in a middle aged Tanzanian man.
  43. Rapid recovery from acute transverse myelitis in an elite female swimmer.
  44. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. 
  45. Acute transverse myelitis and hepatitis C virus.
  46. Transverse myelitis and chronic urticaria in systemic lupus erythematosus. Case report.
  47. Primary biliary cirrhosis complicated by transverse myelitis in a patient without Sjögren’s syndrome.
  48. Transverse myelitis in immunocompetent children.
  49. Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.
  50. Acute transverse myelitis: important role of biology in diagnosis.

Transverse Myelitis in ppt format

Takeda Pharmaceutical Co has presented PHASE III on a new diabetes compound called fasiglifam.TAK 875


Takeda's diabetes drug fasiglifam shines in Phase III

TAK 875

http://www.ama-assn.org/resources/doc/usan/fasiglifam.pdf GET CAS NO STR MW, ETC HERE

Takeda Pharmaceutical Co has presented positive late-stage data on a new diabetes compound called fasiglifam.

The company announced results of a Phase III trial at the Japan Diabetes Society meeting in Kumamoto,

read all at

http://www.pharmatimes.com/Article/13-05-20/Takeda_s_diabetes_drug_fasiglifam_shines_in_Phase_III.aspx

Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis


Paris, France – May 17, 2013– Sanofi  announced today that the pivotal study, JAKARTA, examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), met its primary endpoint in both dose groups. The primary endpoint assessed the proportion of patients achieving >35% reduction of spleen volume. Consistent with data reported in previous trials, the most common adverse events were anemia, diarrhea, nausea and vomiting. Full results will be presented at an upcoming medical congress.

MF is a rare, debilitating and life-threatening hematologic malignancy characterized by abnormal blood cell production and scarring, or fibrosis, in the bone marrow.

“Patients with myelofibrosis in advanced stages are desperately ill and in need of treatments that will improve their outcomes. I am pleased with the results of JAKARTA and would like to thank the patients and the investigators in this trial,” said Debasish Roychowdhury, M.D., Senior Vice President and Head, Sanofi Oncology. “Since Sanofi’s acquisition of the molecule, SAR302503 has moved from Phase I to the completion of pivotal Phase III studies in less than three years, and now we are planning regulatory filings with authorities to make this medicine available for patients.” SAR302503 is a novel, investigational, selective JAK2 inhibitor. Sanofi Oncology is developing SAR302503 for the treatment of the three main types of myeloproliferative neoplasms: primary myelofibrosis, including those previously treated with ruxolitinib; polycythemia vera; and essential thrombocythemia.

About JAKARTA Conducted in 24 countries, the randomized, double-blind, placebo-controlled Phase III JAKARTA study evaluated once-daily oral SAR302503 versus placebo in 289 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. Eligible patients with platelet counts >50,000/μl were randomized to receive a once-daily oral dose of either 400mg of SAR302503, 500 mg of SAR302503 or placebo for twenty-four weeks (six cycles).

The primary endpoint was the proportion of patients with a reduction in spleen volume >35% after 24 weeks of treatment. Key secondary endpoints include the assessment of associated symptoms as measured by total symptom score using six key symptoms as measured by the modified Myelofibrosis Symptom Assessment Form (MF-SAF) diary. Sanofi is also studying the effect of the compound on reversing fibrosis in the bone marrow. After the completion of 24 weeks of treatment or disease progression, crossover from the placebo arm to SAR302503 was allowed.

The JAKARTA study was granted a Special Protocol Assessment (SPA) by the U.S. Food and Drug Administration, signifying that the Phase III trial design, including clinical endpoints, is acceptable to support an application for the granting of marketing authorization in the U.S. More information about the trial is available at www.clinicaltrials.gov.

About JAK2 Inhibition and SAR302503 The normal functioning of the JAK/STAT pathway is key to blood cell development. Dysregulated JAK/STAT signaling is associated with the development of MF and other related myeloproliferative neoplasms (MPN), such as Polycythemia Vera (PV) and Essential Thrombocythemia (ET).

Dysregulation of the JAK/STAT pathway in these diseases occurs with mutations of the JAK2 and MPL genes (notably JAK2V617F and MPLW515L). In addition, up to 50% of patients with MF are considered wild-type, meaning there is no detectable JAK2 or MPL mutations, yet do demonstrate dysregulated JAK2 signaling.

SAR302503 is a novel, investigational, JAK2 kinase inhibitor that selectively inhibits the JAK2 kinase, and in preclinical studies it has demonstrated activity against MF cells containing either JAK2V617F or MPLW515L mutation. As demonstrated in earlier Phase I and II studies, SAR302503 demonstrated activity in MF patients with both wild-type and mutated JAK2 (JAK2V617F). Results from a Phase II study in patients with intermediate-2 or high-risk MF were presented last year and final results are anticipated in Q2 2013. Another Phase II study in ruxolitinib-exposed patients who are either resistant or intolerant to ruxolitinib is ongoing.

About Myelofibrosis Myelofibrosis (MF) is a rare, but serious blood disease characterized by abnormal blood cell production and fibrosis (scarring) within the bone marrow. Scarring in the bone marrow interferes with blood cell production, and the spleen and liver compensate by producing and storing extra blood cells, which cause an enlarged spleen. Of the mutated JAK2 associated myeloproliferative neoplasms, MF carries the poorest prognosis. Median survival for intermediate-2 and high-risk patients is approximately two and a half years; median survival for MF patients overall is approximately six years, and the 10 year risk of the disease transforming to fatal acute myelogenous leukemia (AML) is about 20%.

The exact prevalence of MF is not known. The latest research estimates that the prevalence of MF ranges from 4.2 to 5.6 per 100,000 people in the U.S., or approximately 15,000 patients.

Prevalence estimates in Europe are less clear. People over age sixty are most likely to develop this disease, with men and women equally at risk.

About Sanofi Oncology Sanofi Oncology is a global division of Sanofi based in Cambridge, Massachusetts and Vitry, France. At Sanofi Oncology, the patient is our inspiration. We are dedicated to translating science into effective therapeutics that address unmet medical needs for cancer and organ transplant patients. Through our global organization of talented and passionate employees, we are building a renewed and diversified portfolio, driven by the principles of innovation, personalization and patient access to medicines. We believe that delivering innovative treatment solutions requires collaboration with external experts, which is why we partner our own internal expertise with the best experts in scientific discovery and clinical research around the world.

About Sanofi Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.

Insight into osteoarthritis


Follow New Drug Approvals on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

DISCLAIMER

I , Dr A.M.Crasto is writing this blog to share the knowledge/views, after reading Scientific Journals/Articles/News Articles/Wikipedia. My views/comments are based on the results /conclusions by the authors(researchers). I do mention either the link or reference of the article(s) in my blog and hope those interested can read for details. I am briefly summarising the remarks or conclusions of the authors (researchers). If one believe that their intellectual property right /copyright is infringed by any content on this blog, please contact or leave message at below email address amcrasto@gmail.com. It will be removed ASAP